Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Condition:   Type 2 Diabetes MellitusInterventions:   Drug: Bumetanide;   Drug: DapagliflozinSponsor:   AstraZenecaCompleted - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials